34
BioTOPics 44 | May 2012
BioTOP-Report
Biomaterials
group headed by Prof. Dr. Rainer Haag at Freie Universität Ber-
lin with mivenion GmbH on the research campus Dahlem, which
has successfully characterized a new macromolecular diagnostic
agent for inflammation imaging of rheumatoid arthritis.
The Nanopatterned Biomaterials group of Prof. Dr. Marga Lensen
at the Technical University Berlin has developed a toolbox of tai-
lor-made biomaterials that are patternable in 2D and 3D and at
different length scales, and have tuneable physicochemical prop-
erties, specific degradability profiles and all the characteristics of
a desired biomaterial.
In addition, the Fraunhofer IAP specializes in the targeted devel-
opment of sustainable processes and materials based on natural
and synthetic polymers. The working group of Dr. Joachim Stors-
berg is developing an artificial cornea based on new biomaterials
in order to obtain the different functionalities required to per-
form the needed biological interactions.
The bone healing process can be supported by biochemical or
mechanical intervention and by the introduction of synthetic
scaffolds. In the Department of Biomaterials at the Max Planck
Institute of Colloids and Interfaces in Potsdam, scientists are in-
vestigating the material characteristics of bones at the micro- and
nanometer level. The research group of Britt Wildemann at the
Julius Wolff Institute of the Charité in Berlin has studied the pos-
sibilities for improving bone healing by local application of fac-
tors. Antibiotics are used for infection prevention, while factors
stimulating the bone metabolism are applied to promote healing.
Another example of the use of biomaterials in medicine is the
development of artificial heart valves. Such valves made by Au-
toTissue GmbH were produced by removing cellular components
from xenogenic heart valves and have the major advantage that
they do not calcify in vivo and possess remodelling and growth
potential.
Biomaterials are also essential in the field of drug delivery. For
example, the Paccocath technology for the use of balloon cath-
eters as an effective drug delivery technology was invented in
the Department of Radiology at the Charité, then successfully
developed to market maturity in cooperation with InnoRa GmbH
and Saarland University, and is now being marketed by two com-
panies.
Financing and Added Value
VC Fonds Technologie Berlin was set up as a joint initiative of Investitionsbank
Berlin (IBB) and the State of Berlin. It is co-financed by the European Regional De-
velopment Fund (ERDF).
VC Fonds Technologie
Berlin
Venture Capital
for companies in Berlin
IBB Beteiligungsgesellschaft mbH offers equity financ-
ing for high tech companies in Berlin. For our fund
VC Fonds
Technologie
Berlin
(€52m) we are looking
for investment opportunities in the biotechnology and
medical technology sector.
Our investment approach is based on hands-on
invol vement and active management support for
each portfolio company, delivered by our highly expe-
rienced investment team.
VC Fonds
Technologie
Berlin
not only provides capital, but also helps execute the
business plan.
Are you interested? Please do not hesitate to contact us.
IBB Beteiligungsgesellschaft mbH
Mrs. Ute Mercker / Mr. Christian Seegers
Bundesallee 171
10715 Berlin / Germany
Phone: +49 (0)30 2125-3201
www.ibb-bet.de
Selected portfolio companies:
BioTOP-Report-2012_Anz_IBB-Bet_87x244.indd 1
30.03.2012 10:42:17
BIOCOM AG | Lützowstraße 33–36 | 10785 Berlin | Germany
www.biocom.de | Tel. +49 (0)30 264921-0 | Fax +49 (0)30 264921-11
A AT T G A C AC AC G T TC GC C GAT A AG GA A G T T ATG GA A C C T
GGA C C A T C A C GA TA A A AC GGA C A A T TA C C C GAT TGG A A A
AT C GA A AC C GA A TC A GC C AG T C A A GA A G C T T TC GAC T G C
G TA T T G C A A GGC C AC C AG TAG C AC AC G TGC GGA AC G A C A
TA A A C T GGA AC A AGA TC C AAA GC T T A T TGG A AG TGC C C G
C C A
STudieS & ConSulTinG
GC A TA C C A A TGC ATG C AC GGA
AGG T TC G TA T TA AC T AGA GAT C AT T C T A AC C C T T A T AGC
G T T
ConferenCeS
AAG GAG ATC C C C T TG AC C GGC C GG T T T
TC C C TC C TG GC G G TG TC A A AT C AG TGA C GA C C G T G T AC A
AC A
BookS
TC TC G C C A TA A C G T TGG C T T A A A GC T TA G GC C
GCC ACG
GA A AC G GG T GAC GGG A AT C C A AC C GAC AGA A T T
TGA
T V & Video
AC TC C GC A C AT T TG C GA GC T AGA ACG T A A
GC C TA G GC T C A A A AC GC A T G T GC C G AT C A A GA A T G C A AG
G AT
CorporATe puBliShinG
T T T GGA GA A C T A AC A T C T A G A
AT C C AG C T T AC C AGA TGC AAG AT C T T G GGA GGC A C T GAG
G TA
inTerneT
C TC C GC AC G TC C A AT GGA AT C G TA TA A C C A
AGG G T T TC C AC A
GCC
TGA GC C G AT AT C G TA AGG TGA C A A
GA A
MAGAzineS
G A T TC G TC C TC AG T
ACG
T C A TA G C A A A C T
C AC T C A AC C C A A GGA G T T G TA C TA C TG C GC GA A C T T AC G
C GA
eVenT MAnAGeMenT
TA GC G TC G AC G C AC C A A T G C A C C
GC C A AC GC C C AG TC C A T T AGA GAG TC A TA A GAC GC A GC A
C A A C AC GC T G T T C C C GGA TGC A C A GC C AGG A C T C T T T G C
AGC GGC AAA GC A C AT C C A AGA GA A TGG GAC AC G TGC C AC
AC C GGC GC A T G T T G A C AC A AT C AG C C T G A T TAG C AC C AG
TA A G C T AGA C A A AC A T C T
W e C r e AT e k n o W l e d G e !
T G G
AG T G T T C T C A AG GA A TGA C GA T G T GC C T T G AC C TC G AC G
G T T A C T AC G T C C TGC AT G T T G C GA T T G GGA AGA A A A C T C